导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.10% | 4110/4773 |
| 近一周 | -2.61% | 4088/5465 |
| 近一月 | -6.61% | 4242/5421 |
| 近一季 | -1.34% | 1198/5231 |
| 近半年 | -17.41% | 4243/4920 |
| 近一年 | -19.75% | 3939/4394 |
| 近两年 | 21.44% | 2623/2954 |
| 近三年 | -20.38% | 2166/2253 |
| 成立以来 | -4.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.57% 2370/4961 |
-17.41% 4766/5312 |
- - |
- - |
| 2025 | 8.86% 2889/4813 |
10.16% 334/3635 |
2.32% 1650/4076 |
-0.58% 3929/4524 |
-2.85% 3216/4813 |
| 2024 | -11.92% 2363/3463 |
-11.24% 2421/2808 |
-14.92% 2689/3014 |
18.55% 987/3129 |
-1.63% 1776/3463 |
| 2023 | -7.35% 910/2656 |
14.04% 251/2280 |
-9.12% 2036/2385 |
-9.01% 1765/2515 |
-1.75% 368/2655 |
| 2022 | -16.42% 479/2207 |
-21.86% 1661/1919 |
0.41% 1552/2016 |
-9.69% 296/2113 |
17.96% 46/2208 |
| 2021 | 6.26% 521/1822 |
0.04% 321/1255 |
2.84% 987/1330 |
-8.25% 1117/1466 |
12.57% 80/1822 |
| 2020 | 17.21% 765/1250 |
4.76% 61/1028 |
20.20% 279/1067 |
-1.26% 1063/1164 |
-5.73% 1139/1184 |
| 2019 | 34.10% 415/1092 |
30.93% 222/754 |
-7.94% 575/804 |
5.87% 135/850 |
5.08% 752/918 |
| 2018 | -17.77% 132/834 |
- - |
- - |
- - |
-15.08% 598/691 |
| 2017 | -8.11% 525/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证互联网医疗指数(LOF)A VS. 长安沪深300非周期A(740101) |